CARLSBAD, Calif.–(BUSINESS WIRE)–Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced the publication of a new research study from collaborators at the University of Michigan and New York University (NYU) that further supports the value of the Aventa™ Lymphoma test for identifying rearrangements with diagnostic, prognostic, and potential therapeutic relevance from routine formalin
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
